When you or someone you love is diagnosed with osteosarcoma, the future can suddenly feel full of questions. The osteosarcoma survival rate is generally more favorable when the cancer is found before it has spread beyond the bone, while cancer that has already spread tends to have a more difficult outlook.1

If there’s a bigger question weighing on your mind: is osteosarcoma curable? It’s important to remember that a single survival metric can’t give you that answer.

These statistics reflect overall outcomes within large groups of people with similar diagnoses, but they can’t tell you exactly how one person will respond or how long they will live. Factors such as whether the cancer has spread, where the tumor began, its characteristics, and how it responds to treatment can all shape the outlook. As you gather information, it can help to explore your options, like ITC’s holistic treatment for bone cancer.

For now, here’s what survival statistics can (and can’t) tell you about osteosarcoma prognosis.

Osteosarcoma is the most common primary bone cancer, a type of cancer that most often develops in the long bones near the knee, though it can also involve the pelvis or other sites. Osteosarcoma symptoms can vary depending on where the tumor develops, while incidence rises sharply during the adolescent growth spurt, one reason it’s often grouped with other cancers affecting children and young adults.

What Is the Osteosarcoma Survival Rate?

“Survival rate” describes how many people with the disease are alive a certain number of years after diagnosis. A commonly used measure is the five-year relative survival rate, which compares people with osteosarcoma with similar people in the general population who do not have the cancer.

As a bone sarcoma, how bone cancer is diagnosed typically involves imaging and biopsy findings, which are also used to stage osteosarcoma, sometimes alongside the American Joint Committee on Cancer’s criteria. Current survival information is more often grouped by how far the disease has spread than by the older four-stage classification.

Specifically, the American Cancer Society (ACS) separates the disease into2:

  • “Localized” disease, meaning the cancer is concentrated in its original location
  • “Metastatic” disease, meaning the cancer has spread to distant parts of the body

Certain staging systems also use a “regional” label, which indicates spread to nearby structures but not yet distant areas associated with metastatic cancer.3 Whether the cancer is localized or metastatic remains the single biggest factor doctors use to frame likely outcomes.

The ACS reports that about 60 to 70% of people diagnosed with osteosarcoma recover overall, although the exact outcomes vary substantially according to the disease’s spread.

Your health is our priority. Contact us!

Survival Rate for Localized Osteosarcoma

When osteosarcoma is localized, the cancer stays confined to the bone where it started and hasn’t spread to distant parts of the body. This is generally associated with a more favorable outlook.

The ACS currently reports five-year relative survival rates of approximately 60 to 75% for localized osteosarcoma. These figures are estimates based on groups of patients, so they don’t account for individual nuances within factors like:

  • Tumor size and location
  • Response to treatment
  • Age
  • Overall health

Survival Rate for Metastatic or Distant Osteosarcoma

Metastatic osteosarcoma, or osteosarcoma that has spread beyond the original bone, carries a more complex outlook. The lungs are the most common site of distant spread, although cancer can also spread to other bones or, less often, other organs.

This is different from relapsed osteosarcoma, where the cancer returns after initial treatment; primary metastatic osteosarcoma refers to cases where spread is already present at diagnosis. Local recurrence and survival are closely linked, since a tumor that returns near its original site can be harder to treat than one caught early.

The ACS reports a five-year relative survival rate of approximately 5 to 30% for metastatic osteosarcoma, reflecting the wide range of presentation seen in advanced disease.1

The number and location of metastasis in osteosarcoma, along with the primary osteosarcoma, and how the cancer responds to treatment all affect prognosis.

Is Osteosarcoma Curable?

Many people with osteosarcoma achieve remission. For those wondering, “Can you cure bone cancer?”, the answer depends on the individual case, including factors such as the extent of the disease, tumor characteristics, and response to treatment. Localized cancer generally has a more favorable prognosis than cancer that has spread.

While survival statistics can provide useful context, they can’t determine whether osteosarcoma will be curable in any given case. This depends on a number of factors, including and extending far beyond the rate of spread.

What Affects Osteosarcoma Life Expectancy?

Like any disease, individual outcomes vary, and several factors influence survival. With osteosarcoma, these are some of the most telling factors:

  • Tumor location and size – The position and extent of the tumor can affect how difficult it is to manage.
  • Response to treatment – Researchers commonly assess how much of the tumor has undergone necrosis after treatment, and recent studies continue to find an association between stronger treatment response and better outcomes.
  • Whether the cancer has spread – Localized disease generally has a more favorable statistical outlook than cancer that has reached the lungs or other bones, and metastatic disease at diagnosis is consistently associated with inferior survival.

Because osteosarcoma is one of the more common forms of cancer in children, specialized centers such as St. Jude Children’s Research Hospital focus on treating children with cancer and coordinating pediatric oncology care alongside the National Institutes of Health’s broader childhood cancer research efforts.

Osteosarcoma Mortality Rate: Putting Statistics in Context

When you’re looking at the osteosarcoma mortality rate, you must understand that mortality statistics track deaths from osteosarcoma across a population over a defined period. They provide information about broader patterns within the disease and how those patterns have changed over time.4

Most importantly, these figures can change significantly as detection, research, and treatment approaches improve. A rate based on patient outcomes from the past may not reflect outcomes for people diagnosed today.5 This makes mortality data mostly useful for understanding broader trends in osteosarcoma, relative to the time period when they were recorded.

Why Survival Statistics Can’t Predict One Person’s Outcome

Like many cancer diagnoses, osteosarcoma statistics reflect averages, not individual paths. Two people can have osteosarcoma in the same bone and still have different outcomes because their tumors may differ in size, biology, response to treatment, or extent of spread.

A 2025 survival analysis of a nationwide cohort in Taiwan reinforced these same patterns, finding that tumor response and spread remained the strongest predictors of outcome. Statistics also take time to collect, and are often pooled from large registries such as the National Cancer Data Base and the National Cancer Institute’s SEER program.

The most current ACS figures are based on patients diagnosed between 2015 and 2021, meaning they don’t necessarily capture every development in care since those patients were treated, and long-term survival for people diagnosed today may look different as treatment continues to improve.

For that reason, survival figures are best used as context for a conversation with your healthcare team rather than as a personal life-expectancy calculator.

Holistic Osteosarcoma Support at Immunity Therapy Center

A prognosis can give you numbers, but it can’t (and shouldn’t) tell you what your next chapter has to look like. If you’re weighing your options after an osteosarcoma diagnosis, ITC gives you another place to start, with a closer look at your individual circumstances and care goals.

At our Tijuana cancer center, we offer alternative cancer treatments, built around the individual receiving care. Our approach includes immune-focused therapies and ongoing evaluation so that your care can be highly personalized rather than reduced to a standard protocol.

Schedule a consultation with ITC to discuss your osteosarcoma diagnosis and explore an alternative approach to care.

 

Sources: 

  1. PubMed Central. Osteosarcoma: A Comprehensive Morphological and Molecular Review with Prognostic Implications. https://pmc.ncbi.nlm.nih.gov/articles/PMC12561861/
  2. American Cancer Society. Survival Rates for Osteosarcoma. https://www.cancer.org/cancer/types/osteosarcoma/detection-diagnosis-staging/survival-rates.html
  3. American Cancer Society. Stages and Prognostic Markers of Osteosarcoma. https://www.cancer.org/cancer/types/osteosarcoma/detection-diagnosis-staging/staging.html
  4. National Cancer Institute. Cancer Stat Facts: Bone and Joint Cancer. https://seer.cancer.gov/statfacts/html/bones.html
  5. PubMed Central. Overall Survival and Prognostic Factors in Osteosarcoma: A Nationwide Cohort Study from Taiwan. https://pmc.ncbi.nlm.nih.gov/articles/PMC12942422/

 

At Immunity Therapy Center, all blog content is created to provide high-quality, unbiased, and reliable health information. Each article is written by experienced medical experts, researched using credible medical sources, reviewed for accuracy, fact-checked, and evaluated by ITC’s medical professionals. Our editorial process is designed to reflect current evidence-based information and uphold strong editorial standards.

Articles also include credible third-party sources, listed at the bottom of each page, so readers can access the original source material directly.